W. Ryan et al., A NOVEL CLASS OF POTENT TETRAHYDROCANNABINOLS (THCS) - 2'-YNE-DELTA(8)-THCS AND DELTA(9)-THCS, Life sciences, 56(23-24), 1995, pp. 2013-2020
Citations number
36
Categorie Soggetti
Biology,"Medicine, Research & Experimental","Pharmacology & Pharmacy
A series of 3-alkyl-2'-yne (side chain) acetylenic analogs of Delta(9)
-THC were synthesized and evaluated in vitro and in vivo activity. Ana
logs were evaluated for receptor affinity in a [H-3]CP-55,940 displace
ment assay and for in vivo pharmacological activity in a mouse procedu
re utilizing a tetrad of measures. These compounds represent a prelimi
nary exploration of the consequences of restricting the flexibility of
the side chain regarding cannabimimetic activity. All analogs proved
to have receptor affinities (4-11 nM) that were five to ten times grea
ter than that observed for Delta(9)-THC. However, the in vivo activiti
es of these compounds varied greatly. All analogs proved to possess th
e greatest potency for production of antinociception, with activity si
milar to or less than that observed for the production of hypomotility
, hypothermia, and catalepsy. The most potent analog 11b exhibited an
ED(50) of 0.031 mg/kg in the tail-flick procedure, with values in othe
r measures being between 0.5 and 1.0 mg/kg. The least active compound
(11c), though still possessing a K-I of 11 nM. exhibited ED(50) values
of 3.1 and 9.3 mg/kg for tail-flick and temperature procedures, as we
ll as 41 and 48 mg/kg for ring-immobility and spontaneous locomotor ac
tivity, respectively. This profile (high receptor affinity but low in
vivo potency) would normally be suggestive of a compound with antagoni
st properties (at least for immobility and activity measures). It is u
nclear why these acetylenic analogs were so potent in vitro, while onl
y one (11b) exhibited the degree of in vivo potency anticipated based
upon comparison to values for Delta(9)-THC. It is possible these side
chain modifications do not interfere with receptor recognition, but li
mit receptor activation or second messenger signal transduction. Regar
dless, it is clear these novel analogs provide a basis for the further
exploration of the cannabinoid receptor pharmacophore.